{"filing":{"accession_number":"0001724521-26-000037","cik":"0001724521","ticker":"RCUS","company_name":"Arcus Biosciences, Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"rcus-20260611.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452126000037/rcus-20260611.htm"},"events":[{"id":10851,"run_id":9520,"accession_number":"0001724521-26-000037","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder vote results from Arcus Biosciences' June 11, 2026 annual meeting, covering three proposals: election of Class II directors (Dietmar Berger, David Lacey, Nicole Lambert, and Johanna Mercier), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents detailed vote tallies (votes for, against, withheld, abstentions, and broker non-votes) for each proposal, which is the standard format for Item 5.07 disclosures and constitutes material information about corporate governance outcomes.","company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":7272,"accession_number":"0001724521-26-000037","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Arcus Biosciences' June 11, 2026 annual meeting, covering three proposals: election of Class II directors (Dietmar Berger, David Lacey, Nicole Lambert, and Johanna Mercier), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents detailed vote tallies (votes for, against, withheld, abstentions, and broker non-votes) for each proposal, which is the standard format for Item 5.07 disclosures and constitutes material information about corporate governance outcomes.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:21:53.831649+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7272,"accession_number":"0001724521-26-000037","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Arcus Biosciences' June 11, 2026 annual meeting, covering three proposals: election of Class II directors (Dietmar Berger, David Lacey, Nicole Lambert, and Johanna Mercier), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents detailed vote tallies (votes for, against, withheld, abstentions, and broker non-votes) for each proposal, which is the standard format for Item 5.07 disclosures and constitutes material information about corporate governance outcomes.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:21:53.831649+00:00","company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","filing_date":"2026-06-12"}]}